{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:01Z","timestamp":1791327421969,"version":"4.3.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Subcutaneous immunoglobulin (SCIg) has emerged as an alternative to intravenous administration for patients with primary (PID) and secondary immunodeficiencies (SID), offering benefits such as fewer systemic adverse reactions and greater patient autonomy. However, comprehensive real-world data on SCIg use, including clinical and patient-centered outcomes, remain scarce. This study, conducted by expert immunodeficiency nursing teams, assesses the clinical characteristics, reported adverse effects, and quality-of-life outcomes associated with SCIg therapy with different formulations in patients with PID and SID across Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, cross-sectional study was conducted across 8 immunodeficiency nursing units in Spain, involving 223 adult patients treated with SCIg from 2004 to 2024. Data on demographics, comorbidities, SCIg treatment characteristics, reported adverse events, and quality-of-life metrics (EuroQol-5D-3L, Gij\u00f3n Scale) were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort (61.4% female, mean age: 47.1 years) included 65% PID patients, with common variable immunodeficiency being the most frequent diagnosis (39.8%). SCIg demonstrated good tolerability overall, with no significant differences in global adverse event rates between facilitated 10% (fSCIg) and 20% formulations. However, 10% fSCIg was associated with higher reported frequencies of mild local rash (58.7% vs. 36.9%, p=0.002) and fever (10.6% vs. 1.7%, p=0.01). Quality-of-life scores indicated minimal limitations in mobility and self-care, with a mean subjective health rating of 72.7\/100. Patients using 20% SCIg required fewer educational sessions for self-administration compared to the 10% group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The different SCIg formulations in this large, multicenter cohort was effective and generally well-tolerated, supporting its use for maintaining adequate IgG levels and promoting patient independence in PID and SID. The study\u2019s findings advocate for tailored approaches that optimize patient satisfaction and address individual needs, emphasizing the critical role of dedicated immunodeficiency nursing teams in ensuring safe, effective, and patient-centered SCIg administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1532367","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:59:51Z","timestamp":1739498391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry"],"prefix":"10.3389","volume":"16","author":[{"given":"Sandra","family":"Mart\u00ednez Mercader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Garcia-Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moral Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez Buenaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Escudero Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Montaner Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Balastegui-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Galindo Maycas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Palac\u00ed Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Escobar Palaz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Moreno Mulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Campanero Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Daniel","family":"Hern\u00e1ndez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ruiz-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Guzm\u00e1n Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Dafne","family":"Caba\u00f1ero-Navalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03432.x","article-title":"Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review","volume":"149","author":"Wood","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B3","unstructured":"Hizentra, INN-human normal immunoglobulin: Summary of Product Characteristics"},{"key":"B4","unstructured":"HyQvia, INN-human normal immunoglobulin (SCIg): Summary of Product Characteristics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/1744666X.2016.1155452","article-title":"A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: A systematic review and meta-analysis","volume":"12","author":"Shabaninejad","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis","volume":"120","author":"Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033666","article-title":"Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMI-CVID registry","volume":"13","author":"Caba\u00f1ero-Navalon","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108419","article-title":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study","volume":"215","author":"Legendre","year":"2020","journal-title":"Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological Malignancy-associated secondary immunodeficiency","volume":"101","author":"Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247717","article-title":"Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies","volume":"16","author":"Cinetto","year":"2021","journal-title":"PloS One"},{"key":"B13","article-title":"Evaluaci\u00f3n de la fiabilidad y validez de una escala de valoraci\u00f3n social en el anciano","volume":"23","author":"Garc\u00eda-Gonz\u00e1lez","year":"1999","journal-title":"Aten Primaria"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10875-024-01771-0","article-title":"Insights into patient experiences with facilitated subcutaneous immunoglobulin therapy in primary immune deficiency: A prospective observational cohort","volume":"44","author":"Yalcin Gungoren","year":"2024","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670547","article-title":"Real-world experiences with facilitated subcutaneous immunoglobulin substitution in patients with hypogammaglobulinemia, using a three-step ramp-up schedule","volume":"12","author":"Hustad","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00981","article-title":"Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: A two center, long-term retrospective observation in adults with primary immunodeficiencies","volume":"11","author":"Wiesik-Szewczyk","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01470-2","article-title":"Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: the FIGARO study","volume":"43","author":"Borte","year":"2023","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184524","article-title":"Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: A FIGARO subgroup analysis","volume":"15","author":"Dimou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02649-0","article-title":"Real-world use, safety, and patient experience of 20% Subcutaneous immunoglobulin for primary immunodeficiency diseases","volume":"40","author":"Fasshauer","year":"2023","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01436-4","article-title":"Real-world evidence of tolerability of 20% Subcutaneous immunoglobulin treatment","volume":"43","author":"Rosenbach","year":"2023","journal-title":"J Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12865-016-0169-5","article-title":"Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial","volume":"17","author":"Viallard","year":"2016","journal-title":"BMC Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00705-5","article-title":"Quality of life differences for primary immunodeficiency patients on home SCIG versus IVIG","volume":"39","author":"Anterasian","year":"2019","journal-title":"J Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0562-3","article-title":"Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six hizentra\u00ae Studies","volume":"38","author":"Mallick","year":"2018","journal-title":"J Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0270-1","article-title":"Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study","volume":"35","author":"Vultaggio","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10875-024-01769-8","article-title":"Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in us clinical practice in patients with primary immunodeficiency diseases: results from a post-authorization safety study","volume":"44","author":"Rubinstein","year":"2024","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.09.2474","article-title":"Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases","volume":"123","author":"Stein","year":"2011","journal-title":"Postgrad Med"},{"key":"B28","first-page":"AB247","article-title":"Tolerability of subcutaneous immunoglobulin (SCIG) in patients receiving antiplatelet (AP) and anticoagulant (AC) therapy","volume":"129","author":"Kuryan","year":"2012","journal-title":"J Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12712","article-title":"Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological Malignancies","volume":"38","author":"Dimou","year":"2018","journal-title":"A Single-Center Retrospective Analysis Anticancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-0592-5","article-title":"Health-related quality of life in patients with CVID under different schedules of immunoglobulin administration: prospective multicenter study","volume":"39","author":"Pulvirenti","year":"2019","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:59:54Z","timestamp":1739498394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1532367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1532367"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1532367","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"article-number":"1532367"}}